Lerociclib
Lerociclib，也称为G1T38，是一种口服，有效和选择性的CDK4 / 6抑制剂，用于抗肿瘤的治疗。研究表明，Lerociclib (G1T3) 是CDK4 / 6的竞争性纳摩尔抑制剂，对CDK4-cyclin D1和CDK6-cyclin D3具有高度选择性。 Lerociclib (G1T3) 在Rb空细胞中表现出低EC50> 3μM。在体内，每天用Lerociclib (G1T3)口服治疗可在HER2 / neu GEMM和MCF7异种移植乳腺癌模型中显着，持久地抑制肿瘤生长。
Lerociclib HCl (G1T38 HCl) may be provided.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Lerociclib |
|---|---|
| Iupac 化学名称 | 2'-((5-(4-isopropylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one |
| 同义词 | G1T38; G1T-38; G1T 38; G1-T38; G1 T-38; G1 T38; Lerociclib |
| 英文同义词 | G1T38; G1T-38; G1T 38; G1-T38; G1 T-38; G1 T38; Lerociclib |
| 分子式 | C26H34N8O |
| 分子量 | 474.613 |
| Smile | CC(C)N(CC1)CCN1C(C=N2)=CC=C2NC3=NC=C4C(N(C5(CCCCC5)CNC6=O)C6=C4)=N3 |
| InChiKey | YPJRHEKCFKOVRT-UHFFFAOYSA-N |
| InChi | InChI=1S/C26H34N8O/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31) |
| Cas号 | 1628256-23-4 (free base) |
| 相关CAS号 | 2097938-59-3 (HCl) ; 1628256-23-4 (free base) |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | 黄色固体 |
|---|---|
| 纯度 | 98% |
| 存储 | 短期（几天到几周）为0-4摄氏度，长期（几个月）为-20摄氏度 |
| 可溶性 | 可溶于DMSO |
| 处理方式 | Avoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation. |
| 运输条件 | 作为非危险化学品在环境温度下装运。这种产品在正常运输和海关工作期间可以稳定几周 |
| 海关编码 | 2933999701 |
| Targets | CDK4/6 inhibitor |
|---|---|
| Mechanism | Lerociclib (G1T38 ) is a novel, selective,differentiated oral CDK4/6 inhibitor with biochemical IC50 values of 1 nM, 2 nM and 28 μnM for CDK4, CDK6 and CDK9 respectively. Lerociclib (G1T38) with potential use in combination with other targeted therapies in certain types of breast and lung cancer. |
| Cell study | |
| Animal study | |
| Clinical study |
1: Bisi JE, Sorrentino JA, Jordan JL, Darr DD, Roberts PJ, Tavares FX, Strum JC. Preclinical development of G1T38: A novel, potent and selective inhibitor ofcyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. Oncotarget. 2017 Mar 15. doi: 10.18632/oncotarget.16216. [Epub ahead of print] PubMed PMID: 28418845.
2: Stice JP, Wardell SE, Norris JD, Yllanes AP, Alley HM, Haney VO, White HS, Safi R, Winter PS, Cocce KJ, Kishton RJ, Lawrence SA, Strum JC, McDonnell DP. CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC. Mol Cancer Res. 2017 Jun;15(6):660-669. doi: 10.1158/1541-7786.MCR-17-0028. Epub 2017 Feb 16. PubMed PMID: 28209757.
.png)